The association of GSTT1 deletion polymorphism with lung cancer risk among Chinese population: evidence based on a cumulative meta-analysis

Yadong Wang¹
Haiyan Yang²
Haiyu Wang¹

¹Department of Toxicology, Henan Center for Disease Control and Prevention, Zhengzhou, People’s Republic of China; ²Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou, People’s Republic of China

Objective: Previous studies investigating the relationship between glutathione S-transferase T1 (GSTT1) gene deletion polymorphism and lung cancer risk among Chinese population produced inconsistent results. To obtain a precise conclusion, we performed this meta-analysis to evaluate the association between GSTT1 deletion polymorphism and lung cancer risk among Chinese population.

Methods: The databases of Medline/PubMed, Embase, Web of Science, Wanfang Med Online, and Chinese National Knowledge Infrastructure were searched. The strength of the association was assessed by odds ratio (OR) with 95% confidence intervals (95% CI).

Results: Overall, we found an increased lung cancer risk among subjects carrying GSTT1 null genotype compared with those carrying present genotype (OR =1.31, 95% CI: 1.12–1.52) on the basis of 20 studies with 3,351 cases and 4,683 controls. We also observed an increased risk of lung cancer among subjects carrying GSTT1 null genotype compared with those carrying present genotype in stratified analyses (OR =1.31, 95% CI: 1.11–1.55 for healthy subjects-based control; OR =2.29, 95% CI: 1.84–2.85 for squamous cell carcinoma and OR =1.47, 95% CI: 1.22–1.77 for adenocarcinoma, respectively).

Conclusion: This meta-analysis suggested that GSTT1 deletion polymorphism might contribute to lung cancer risk among Chinese population.

Keywords: lung cancer, risk, GSTT1, polymorphism, meta-analysis, Chinese

Introduction

Lung cancer was the most commonly diagnosed cancer as well as the leading cause of cancer death in males globally, and it was the fourth most commonly diagnosed cancer and the second leading cause of cancer death among females in 2008.¹ In the United States, there were about 228,190 estimated new lung cancer cases and 159,480 estimated deaths in 2013.² In the People’s Republic of China, lung cancer increased 465% during the past 30 years and became the leading cause of cancer death in the current decade. It is estimated that over one million Chinese will be diagnosed with lung cancer by the year 2025.³

Lung cancer has been considered as a disease determined solely by environmental exposure, such as exposure to cigarette smoke and asbestos.⁴ However, only a small proportion of persons who are exposed to such risk factors will develop lung cancer, which suggests that an individual’s susceptibility might contribute to lung cancer risk. Recently, more and more results have supported the hypothesis that common genetic variations of drug-metabolizing enzyme genes may be of importance in determining an individual’s sensitivity to develop lung cancer.⁵

Glutathione S-transferase theta-1 (GSTT1), a member of glutathione S-transferases (GSTs), is a kind of phase II detoxification enzyme that is involved in detoxifying...
several kinds of carcinogens such as benzo(a)pyrene present in tobacco smoke. GSTT1 deletion polymorphism is known to abolish enzyme activities and modulate lung cancer risk. Lan et al., for the first time, explored the association of GSTT1 deletion polymorphism with lung cancer risk in the Chinese population in 1999. After that, a series of epidemiological studies investigated this association in the Chinese population successively. However, the conclusions by previous studies remained controversial rather than conclusive. This urged us to perform this meta-analysis using the updated data, which aims at deriving a precise estimate of GSTT1 deletion polymorphism associated with lung cancer risk among Chinese population.

Materials and methods

Literature source and analytical methods

Systematic searches were conducted through the databases of Medline/PubMed, Embase, Web of Science, Wanfang Med Online, and Chinese National Knowledge Infrastructure, with the following keywords: “lung cancer” or “lung neoplasm” or “lung carcinoma” and “GSTT1” or “glutathione S-transferase T1” and “polymorphism” and “Chinese” or “China.” The starting date for searched publications was January 1, 1990 and the ending date of searched publications was January 31, 2015. We also searched the reference list of relevant publications to identify additional studies manually.

Criteria for inclusion: 1) the subjects of study must be Chinese; 2) papers should include GSTT1 deletion polymorphism and lung cancer risk; 3) case–control study and cohort study; and 4) complete data on genotype of GSTT1 deletion polymorphism for calculating odds ratio (OR) with 95% confidence intervals (95% CI). Accordingly, reviews and repeated or overlapping literatures were excluded. If studies contained overlapping cases and/or controls, the latest publication including more information was preferred. We only included journal articles, and not dissertations.

In total, 38 published studies were identified which studied the association between GSTT1 deletion polymorphism and lung cancer risk among Chinese population. We reviewed all papers in accordance with the aforementioned criteria defined and excluded 5 dissertations, 4 reviews, and 9 overlapping articles. Therefore, 20 studies were selected for our study.

Data extraction

Data were extracted and tabulated first, and then inputted into an electronic database. The following information was extracted from each study: authors’ names, year of publication, area, source of control, number of cases and controls, genotype frequency, and stratified factors. Characteristics of individual studies are summarized in Table 1.

Table 1 General information of selected studies in this meta-analysis

<table>
<thead>
<tr>
<th>Study</th>
<th>Area</th>
<th>Source of control</th>
<th>Number of cases</th>
<th>Number of controls</th>
<th>Stratified factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cao et al</td>
<td>Hunan</td>
<td>Healthy subjects</td>
<td>104</td>
<td>205</td>
<td>Histological type</td>
</tr>
<tr>
<td>Chan-Yeung et al</td>
<td>Hong Kong</td>
<td>Healthy subjects</td>
<td>229</td>
<td>197</td>
<td></td>
</tr>
<tr>
<td>Fowke et al</td>
<td>Shanghai</td>
<td>Healthy subjects</td>
<td>208</td>
<td>784</td>
<td></td>
</tr>
<tr>
<td>He and Chan</td>
<td>Yunnan</td>
<td>Healthy subjects</td>
<td>61</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Jiang et al</td>
<td>Inner Mongolia</td>
<td>Healthy subjects</td>
<td>322</td>
<td>456</td>
<td>Smoke</td>
</tr>
<tr>
<td>Lan et al</td>
<td>Yunnan</td>
<td>Healthy subjects</td>
<td>122</td>
<td>122</td>
<td></td>
</tr>
<tr>
<td>Liang et al</td>
<td>Jiangsu</td>
<td>Hospitalized patients</td>
<td>152</td>
<td>152</td>
<td>Histological type</td>
</tr>
<tr>
<td>Liang et al</td>
<td>Guangxi</td>
<td>Hospitalized patients</td>
<td>68</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Liu et al</td>
<td>Jilin</td>
<td>Healthy subjects</td>
<td>100</td>
<td>135</td>
<td>Smoke</td>
</tr>
<tr>
<td>London et al</td>
<td>Shanghai</td>
<td>Healthy subjects</td>
<td>232</td>
<td>710</td>
<td></td>
</tr>
<tr>
<td>Ma et al</td>
<td>Sichuan</td>
<td>Healthy subjects</td>
<td>125</td>
<td>125</td>
<td>Sex</td>
</tr>
<tr>
<td>Pan et al</td>
<td>Jiangxi</td>
<td>Hospitalized patients</td>
<td>523</td>
<td>523</td>
<td>Smoke, histological type and sex</td>
</tr>
<tr>
<td>Qi et al</td>
<td>Gansu</td>
<td>Hospitalized patients</td>
<td>53</td>
<td>72</td>
<td>Smoke, histological type and age</td>
</tr>
<tr>
<td>Wang et al</td>
<td>Beijing</td>
<td>Hospitalized patients</td>
<td>112</td>
<td>119</td>
<td>Smoke</td>
</tr>
<tr>
<td>Wang et al</td>
<td>Henan</td>
<td>Healthy subjects</td>
<td>77</td>
<td>107</td>
<td>Histological type</td>
</tr>
<tr>
<td>Wang et al</td>
<td>Henan</td>
<td>Healthy subjects</td>
<td>209</td>
<td>256</td>
<td></td>
</tr>
<tr>
<td>Yuan et al</td>
<td>Sichuan</td>
<td>Healthy subjects</td>
<td>150</td>
<td>152</td>
<td>Smoke and histological type</td>
</tr>
<tr>
<td>Zhang et al</td>
<td>Sichuan</td>
<td>Healthy subjects</td>
<td>150</td>
<td>152</td>
<td></td>
</tr>
<tr>
<td>Zhang et al</td>
<td>Guangdong</td>
<td>Healthy subjects</td>
<td>161</td>
<td>165</td>
<td>Smoke, histological type and sex</td>
</tr>
<tr>
<td>Zhao et al</td>
<td>Singapore</td>
<td>Hospitalized patients</td>
<td>233</td>
<td>187</td>
<td></td>
</tr>
</tbody>
</table>
by Cochrane $Q$ statistics test.\textsuperscript{43} Data were combined using either a fixed-effects model or a random-effects model depending on the results of heterogeneity test. A fixed-effects model is used when there is no heterogeneity, while a random-effects model is used when heterogeneity exists.\textsuperscript{43} Cumulative meta-analysis was performed to investigate the tendency of results by accumulating single study year by year.\textsuperscript{44} Funnel plot was drawn to evaluate the publication bias. Egger’s test (an adjusted rank correlation test is proposed as a technique for identifying publication bias)\textsuperscript{45} and Begg’s test (a linear regression approach is used to measure funnel plot asymmetry on the natural logarithm scale of the OR)\textsuperscript{46} were applied to assess the symmetry of funnel plot. Sensitivity analysis was performed by deleting one study each time.\textsuperscript{44}

All of the statistical analyses were performed using Review Manager (Version 5.0.24, The Cochrane Collaboration) and STATA 10.0 software package (Stata Corporation, College Station, TX, USA). All the tests were two-sided; a $P$-value of 0.05 for any test or model was considered to be statistically significant.

## Results

### Meta-analysis databases

A database was created according to the extracted information from selected articles. Some essential information is listed in Table 1. It indicates the study (first author et al), year of publication, area, source of control, number of cases and controls, and stratified factors. There were a total of 20 studies, with 3,351 cases and 4,683 controls concerning the association of $GSTT1$ deletion polymorphism with lung cancer risk among Chinese population. The frequency of $GSTT1$ null genotype was 53.4% and 48.0% in cases and controls, respectively.

### Test of heterogeneity

Table 2 shows the association between $GSTT1$ deletion polymorphism and lung cancer risk among Chinese population. Our results showed that there was no heterogeneity for $GSTT1$ null genotype versus present genotype in the subgroup analyses of squamous cell carcinoma and adenocarcinoma. Therefore, we calculated the summary ORs for them with a fixed-effects model. Random-effects model was used to calculate the summary ORs for the rest.

### Quantitative data synthesis

Table 2 listed the summary ORs of the association between $GSTT1$ deletion polymorphism and lung cancer risk among Chinese population on the basis of 3,351 cases and 4,683 controls. Overall, there was a statistically significant correlation of $GSTT1$ null genotype with an increased lung cancer risk among Chinese population, and the summary OR was 1.31 (95% CI: 1.12–1.52; Figure 1). The cumulative meta-analysis accumulated the studies according to the year of publications, which may determine whether new studies are needed or not. Our results showed that there was still a significant association between $GSTT1$ deletion polymorphism and lung cancer risk among Chinese population; the cumulative OR was 1.31 with 95% CI: 1.12–1.52 (Figure 2).

In subgroup analysis for source of control, we observed an increased risk of lung cancer among subjects carrying $GSTT1$ null genotype compared with those carrying present genotype in healthy subjects-based controls (OR = 1.31, 95% CI: 1.11–1.55), but not in hospitalized patient-based controls (OR = 1.28, 95% CI: 0.89–1.83). We observed an increased risk of lung squamous cell carcinoma and lung adenocarcinoma among subjects carrying $GSTT1$ null genotype compared with those carrying present genotype in stratified analysis by histological subtype (OR = 2.29, 95% CI: 1.51–3.36).

### Table 2 Combined ORs on the relation of the $GSTT1$ deletion polymorphism to lung cancer risk among Chinese population

<table>
<thead>
<tr>
<th>Null versus present</th>
<th>Cases/controls</th>
<th>Heterogeneity test</th>
<th>Combined OR (95% CI)</th>
<th>Hypothesis test</th>
<th>df</th>
<th>Begg’s test</th>
<th>Egger’s test</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$Q$</td>
<td>$P$-value</td>
<td>Combined OR (95% CI)</td>
<td>$Z$</td>
<td>$P$-value</td>
<td>$Z$</td>
</tr>
<tr>
<td>Total</td>
<td>3,351/4,683</td>
<td>46.23</td>
<td>0.0005</td>
<td>1.31 (1.12–1.52)</td>
<td>3.44</td>
<td>0.0006</td>
<td>19</td>
</tr>
<tr>
<td>Stratified by source of control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>2,210/3,560</td>
<td>27.75</td>
<td>0.01</td>
<td>1.31 (1.11–1.55)</td>
<td>3.14</td>
<td>0.02</td>
<td>13</td>
</tr>
<tr>
<td>Hospitalized patients</td>
<td>1,141/1,123</td>
<td>18.13</td>
<td>0.003</td>
<td>1.28 (0.89–1.83)</td>
<td>1.34</td>
<td>0.18</td>
<td>5</td>
</tr>
<tr>
<td>Stratified by smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smokers</td>
<td>680/673</td>
<td>18.09</td>
<td>0.003</td>
<td>1.54 (0.97–2.43)</td>
<td>1.84</td>
<td>0.07</td>
<td>5</td>
</tr>
<tr>
<td>Nonsmokers</td>
<td>636/884</td>
<td>15.45</td>
<td>0.02</td>
<td>1.03 (0.70–1.51)</td>
<td>0.14</td>
<td>0.89</td>
<td>6</td>
</tr>
<tr>
<td>Stratified by histological subtype</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>520/1,113</td>
<td>8.66</td>
<td>0.12</td>
<td>2.29 (1.84–2.85)</td>
<td>7.45</td>
<td>&lt;0.00001</td>
<td>5</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>691/1,350</td>
<td>4.36</td>
<td>0.63</td>
<td>1.47 (1.22–1.77)</td>
<td>4.03</td>
<td>0.0001</td>
<td>6</td>
</tr>
</tbody>
</table>

**Abbreviations**: OR, odds ratio; $GSTT1$, glutathione S-transferase T1; CI, confidence interval.
Figure 1 Forest plot of OR for GSTT1 deletion polymorphism associated with lung cancer risk among Chinese population.

Abbreviations: GSTT1, glutathione S-transferase T1; OR, odds ratio; CI, confidence interval; M–H, Mantel–Haenszel test.

Figure 2 Forest plot for cumulative meta-analysis of OR for GSTT1 deletion polymorphism associated with lung cancer risk among Chinese population.

Abbreviations: GSTT1, glutathione S-transferase T1; OR, odds ratio.
95% CI: 1.84–2.85 and OR = 1.47, 95% CI: 1.22–1.77, respectively). We did not observe any association between GSTT1 null genotype and lung cancer risk stratified by smoking status (OR = 1.54, 95% CI: 0.97–2.43 for smokers and OR = 1.03, 95% CI: 0.70–1.51 for nonsmokers, respectively; Table 2).

Bias diagnosis
Publication bias was examined by using funnel plot analysis. The shape of the funnel plot seemed to be approximately symmetrical (Figure 3). Both Egger’s test and Begg’s test suggested that publication bias might have few effects on the summary estimates, except for the subgroup analysis of squamous cell carcinoma, owing to *P*-value being equal to 0.024 in Begg’s test.

Sensitivity analysis
We performed a sensitivity analysis to determine the influence of individual dataset on the summary OR by consecutively deleting individual studies. The combined OR was not significantly altered by deleting each selected study sequentially, which indicated that our results were stable and robust (Figure 4).

Discussion
GSTT1 gene is mapped on chromosome 22q11.23. It is 8,146 bp in length, consisting of five exons and four introns, which encodes a cytoplasmic protein of 240 amino acid residues with a molecular weight of 28-kDa. GSTT1 gene has a functional and nonfunctional allele. Homozygosity for the nonfunctional allele of GSTT1 (null genotype) gene causes an absence of GSTT1 enzyme activity. Individuals who carry homozygous deletions in this gene are thought to be at increased risks for malignancies. Studies have shown that the...
GSTT1 gene deletion have effects on survival and clinical outcomes of lung cancer patients. Ruano-Ravina et al reported that lung cancer patients with deleted GSTT1 genotype had a significantly shorter survival than those with present GSTT1 genotype. Sreeja al reported that the GSTT1 /-- genotype along with stage was significantly associated with overall survival and was found to be an independent prognostic factor for shorter lung cancer survival. Gonlugur al’s study showed that none of the patients with GSTT1 null genotype, but 30% of the patients with GSTT1-positive genotype had liver metastasis among 81 lung cancer patients.

Several meta-analyses explored the association of GSTT1 null genotype with the development of several kinds of cancers among Chinese population. In this paper, we performed a systematic literature review to comprehensively evaluate the association of GSTT1 deletion polymorphism with lung cancer risk among Chinese population. We also evaluated the possible effect modifications by source of control, smoking status, and histological subtype. In summary, we observed an increased lung cancer risk among Chinese population with GSTT1 null genotype compared with those carrying present genotype. To our knowledge, four published papers have addressed the association between GSTT1 deletion polymorphism and lung cancer risk among Chinese population. However, the conclusions are mixed, for example, three previous meta-analyses observed a positive association between GSTT1 null genotype and an increased lung cancer risk among Chinese population, but one not. Furthermore, there are several key limitations in all four previous meta-analyses. Namely, one eligible paper published before 2010 was not included in Wang et al’s paper; two eligible papers published before 2013 were not included in Liu et al’s paper and Gui et al’s paper. Moreover, the number of cases and controls reported by Gui et al for Chan-Yeung et al’s study did not seem in line with the data in Chan-Yeung et al’s original publication; for Liu et al’s paper, two overlapping papers were not excluded and two eligible papers published before 2013 were not included. Therefore, the conclusions from them are not entirely reliable. Our cumulative meta-analysis included 20 selected studies, with 3,351 cases and 4,683 controls on the basis of the updated data. We believed that this current meta-analysis presented a precise estimate of the association between GSTT1 deletion polymorphism and lung cancer risk among Chinese population.

Cigarette smoke is an evident risk factor for lung cancer, and GSTT1 gene is involved in metabolizing various carcinogens present in cigarette smoke. To address the effect of cigarette smoke on the correlation of GSTT1 deletion polymorphism with lung cancer risk, subgroup analysis was conducted in the light of smoking status. We did not observe any association of GSTT1 null genotype with increased risk of lung cancer among smokers or nonsmokers, which might be owing to the relatively small sample size (680 cases in smokers and 636 cases in nonsmokers).

To our knowledge, lung cancer consists of at least three major histological subtypes: squamous cell carcinoma, adenocarcinoma, and small-cell carcinoma. Studies have shown that the development of squamous cell carcinoma and small-cell carcinoma is more often attributed to cigarette smoking, whereas adenocarcinoma is more weakly associated with cigarette smoking than those two subtypes, indicating there is a difference in carcinogenic processes among different histological subtypes of lung cancer. Therefore, a subgroup analysis was performed according to histological subtype. We observed a statistically significant association of GSTT1 deletion polymorphism with an increased risk of squamous cell carcinoma and adenocarcinoma. We did not perform subgroup analysis in additional histological subtypes, since the sample size for those was relatively small.

There are some potential limitations inherent in this meta-analysis. First, only published articles were included in this study, which may cause publication bias. To address this issue, both Egger’s test and Begg’s test were applied in this study. Our results demonstrated that the likelihood of key publication bias was negligible in this current meta-analysis. Second, although some confounders were matched perfectly between cases and controls for each study at the beginning of study design, different study might have different eligibility criteria for subjects and different source of controls, which should be considered when expounding the combined effects. When the subgroup analysis was conducted by source of control, the association with GSTT1 null genotype was much stronger in the conducted analysis of studies including healthy subjects as controls (OR = 1.31, 95% CI: 1.11–1.55) than that of studies including hospitalized patients controls (OR = 1.28, 95% CI: 0.89–1.83), indicating that the distribution frequency of GSTT1 null genotype in the hospitalized patients-based control groups might not be representative of the general population. Third, this meta-analysis is based on an unadjusted estimate; thus, a more precise analysis depending on adjusted factors should be conducted in the future study.

In summary, this meta-analysis found that GSTT1 null genotype was associated with an increased risk of lung cancer among Chinese population. Studies with larger sample size.
are required to evaluate gene–gene and gene–environment interactions on GSTT1 deletion polymorphism and lung cancer risk among Chinese population further.

Disclosure

The authors report no conflicts of interests in this work.

References